



## Hepatitis B Virus Infection: From Cell Entry to Carcinogenesis. Understanding Viral Replication, Cell Pathogenesis, Disease and Treatments

Guest Editor:

**Dr. Rodrigo A. Villanueva**

Centro Ciencia & Vida, Fundación  
Ciencia & Vida, Avda. Zañartu  
1482, Nunoa, Santiago 7780272,  
Chile

Deadline for manuscript  
submissions:

**closed (30 April 2023)**

### Message from the Guest Editor

Human hepatitis B virus (HBV) infection can progress to severe chronic diseases and hepatocellular carcinoma, which unfortunately are currently highly prevalent worldwide. While the availability of a prophylactic vaccine has reduced new cases over the decades, a therapeutic solution for chronic hepatitis B is still unavailable. On the other hand, important advances have been achieved on HBV virology. However, a comprehensive knowledge of some fundamental steps and factors involved in virus replication, persistence, and pathogenesis are still unreachable, and therefore, more research is required to accomplish strategies controlling HBV. To contribute new knowledge about this serious human pathogen, this Special Issue will bring together original research papers or review manuscripts on HBV infection with focus on viral replication and persistence, cell pathogenesis, hepatic disease, and anti-viral treatments.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)